Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

SGHTBullishAnalyst Ratingnews

High materiality8/10

Sight Sciences gets Buy rating with 70% upside on glaucoma and reimbursement tailwinds

Oct 15, 2026, 2:15 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

A new Buy rating with a $14 target implies ~70% upside, likely to prompt a re-rating and sharpen focus on SGHT’s growth avenues (OMNI and TearCare) and reimbursement tailwinds; however, valuation remains sensitive to reimbursement stability and profitability trajectory.

AI summary

What happened, with direct paths to the underlying reporting

H.C. Wainwright launched coverage on Sight Sciences with a Buy rating and a $14 price target, signaling a potential near-term re-rating of SGHT on its glaucoma and dry-eye platforms. Growth drivers include the OMNI glaucoma system and TearCare, plus broader reimbursement from Aetna, alongside improving sales efficiency. Risks remain from reimbursement variability and ongoing losses, but 2026–27 revenue growth targets provide a constructive path to profitability.

W.C. Wainwright initiates SGHT coverage with Buy rating and $14 target.
OMNI glaucoma and TearCare cited as key growth drivers for SGHT.
Aetna expands glaucoma coverage, adding about 25 million commercially insured members.
Q2 revenue up 19.5% YoY to $23.4m; dry eye revenue up 703% to $2.7m.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.